Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €50.81 EUR
Change Today +1.45 / 2.94%
Volume 8.5K
NOVA On Other Exchanges
Symbol
Exchange
OTC US
New York
Mexico
Frankfurt
Frankfurt
As of 3:39 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Open
€50.50
Previous Close
€49.36
Day High
€50.88
Day Low
€48.87
52 Week High
03/27/15 - €51.00
52 Week Low
04/14/14 - €30.18
Market Cap
134.7B
Average Volume 10 Days
4.3K
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
€0.74
Dividend Yield
1.35%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,957 Employees
Last Reported Date: 02/5/15
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk to Launch Novoeight® in the United States for People with Hemophilia A

Novo Nordisk announced the company will launch Novoeight® (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight® offers purity, reliability, and enhanced portability, with the higher storage temperature for the longest period of time compared with other marketed recombinant Factor VIII products up to 86 degrees F for 12 months.1 It can be kept at that temperature for up to 4 hours after reconstitution, giving it the longest postreconstitution storage time.1 Novoeight® offers purity through a 5-step purification process. It was shown to be safe and effective in clinical trials with zero inhibitors confirmed in 213 previously treated patients with hemophilia A.1 Novo Nordisk plans to make Novoeight® available by mid-April 2015. Hemophilia patients have unique, individualized needs, so it is critical for them to have access to different therapies. The US Food and Drug Administration (FDA) approved Novoeight® for use in adults and children with hemophilia A for the control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes based on results from the guardian trials one of the larger and most comprehensive clinical trial programs of a recombinant Factor VIII to date.1 Novoeight® is the latest hemophilia therapy from Novo Nordisk to build on the company's long-standing heritage in rare bleeding disorders, which began with the development of its first recombinant factor therapy more than 20 years ago. Novo Nordisk is confident in the Novoeight® offering and is supporting eligible patients who try the product with a satisfaction guarantee.

Novo Nordisk A/S to Resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US

Novo Nordisk announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month. The cardiovascular outcomes trial for Tresiba® (insulin degludec), DEVOTE, was initiated in October 2013 and the required number of major adverse cardiovascular events (MACE) for the prespecified interim analysis were accumulated by the end of January 2015. The result of an interim analysis carries a higher level of uncertainty than the final study results as this preliminary estimate is built on a substantially lower number of observations. In addition to the data from the interim analysis of DEVOTE, the Class II Resubmission will comprise a safety update including data from all clinical trials with insulin degludec as well as an overview of postmarketing data. Following the submission of the Class II Resubmission, the FDA is expected to communicate either its acceptance of the filing or issue an `Incomplete Response Letter'. This usually occurs within a month of resubmission. To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data. Novo Nordisk management does not have access to the results of the interim analysis. The trial is expected to be completed in the second half of 2016.

Novo Nordisk Completes Phase 3a Trials Comparing Faster-Acting Insulin as Part with NovoRapid in People with Type 1 and Type 2 Diabetes

Novo Nordisk announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset® 1 and onset®2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid (insulin aspart) in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively. Both trials achieved their primary objectives by demonstrating that treatment with faster-acting insulin aspart is non-inferior to NovoRapid® with regard to lowering of HbA1c. For people with type 1 diabetes, the HbA1c lowering achieved with faster-acting insulin aspart was statistically significantly larger than that achieved with NovoRapid ® when the insulins were given at mealtime. In addition, treatment with faster-acting insulin aspart was associated with less increase of postprandial glucose than NovoRapid® during meal tests in both trials. In both trials, the previously reported safety and tolerability profiles of faster-acting insulin aspart and NovoRapid were confirmed, and there were no apparent differences between the two treatment groups with respect to adverse events and other safety parameters. Novo Nordisk expects to file faster-acting insulin aspart for regulatory review in the US and EU around the turn of the year. Onset® 1 In onset® 1, a total of 1,290 people with type 1 diabetes had their basal insulin therapy optimised during an eight-week run-in period. After the run-in period, 1,143 people with type 1 diabetes, had successfully optimised their basal insulin therapy following conversion to Levemir, were randomised in a double-blinded fashion to addition of either faster-acting insulin aspart or NovoRapid at mealtimes for 52 weeks, or to open- label treatment with faster-acting insulin aspart post-meal for a period of 26 weeks. After 26 weeks, the mean baseline HbA1c of 7.6% was reduced by 0.32%, 0.17% and 0.13% for people treated with mealtime faster-acting insulin aspart, mealtime NovoRapid and post-meal faster-acting insulin aspart, respectively. This confirmed the trial's primary objective of non-inferiority in HbA1c improvement for mealtime faster- acting insulin aspart compared to NovoRapid®. The HbA1c improvement with mealtime faster-acting insulin aspart was statistically significantly greater than with NovoRapid and the improvement with post-meal faster-acting insulin aspart was non-inferior compared with NovoRapid at mealtime. In the trial, people treated with faster-acting insulin aspart achieved statistically significantly larger improvements in both 1- and 2-hour postprandial glucose (PPG) increments during a meal test compared with people treated with NovoRapid. The difference in PPG increment was achieved at 1 hour and was more than 1 mmol/l. The overall rate of severe or blood glucose confirmed hypoglycaemia was similar for faster-acting insulin aspart and NovoRapid. A higher rate of hypoglycaemia was observed for mealtime faster-acting insulin aspart within the first hour after start of a meal. In onset® 2, a total of 881 people with type 2 diabetes inadequately controlled on a combination of basal insulin and oral antidiabetic drugs had their basal therapy optimized during an eight-week run-in period. The 689 people who had reached the prespecified HbA1c target of 7.0­9.5% in the run-in period were randomised to addition of either faster-acting insulin aspart or NovoRapid as mealtime insulin for a period of 26 weeks. After 26 weeks, the mean HbA1c had improved from around 7.9% to around 6.6% for both people treated with faster-acting insulin aspart and people treated with NovoRapid. This confirmed the primary objective of non-inferiority in HbA1c. In the trial, people treated with faster-acting insulin aspart achieved a statistically significantly larger improvement of around 0.6 mmol/l in 1-hour PPG increment during a meal test compared with people treated with NovoRapid. The improvement in 2-hour PPG increment was numerically larger for people treated with faster-acting insulin aspart compared with NovoRapid but the difference was not statistically significant. The overall rate of severe or blood glucose confirmed hypoglycaemia was similar for faster-acting insulin aspart and NovoRapid. A higher rate of hypoglycaemia was observed for faster-acting insulin aspart within the first two hours after start of a meal.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €50.81 EUR +1.45

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $58.24 USD +0.59
Actavis plc $304.76 USD +1.20
Amgen Inc $164.31 USD +1.72
Biogen Inc $431.62 USD +1.75
Bristol-Myers Squibb Co $65.76 USD +0.50
View Industry Companies
 

Industry Analysis

NOVA

Industry Average

Valuation NOVA Industry Range
Price/Earnings 33.0x
Price/Sales 9.7x
Price/Book 21.4x
Price/Cash Flow 26.5x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.